Combination therapy for treating cyclooxygenase-2 mediated diseases or conditions in patients at risk of thrombotic cardiovascular events

Details for Australian Patent Application No. 2005206227 (hide)

Owner Merck Frosst Company

Inventors Dufresne, Claude; Sturino, Claudio F.; Gallant, Michel; Guay, Daniel; Aspiotis, Renee; Berthelette, Carl; Wang, Zhaoyin; Li, Lianhai; Lacombe, Patrick

Agent Spruson & Ferguson

Pub. Number AU-A-2005206227

PCT Pub. Number WO2005/070868

Priority 60/539,912 27.01.04 US

Filing date 25 January 2005

Wipo publication date 4 August 2005

International Classifications

A61K 31/22 (2006.01)

A61K 31/04 (2006.01) - Nitro compounds

A61K 31/045 (2006.01) - Hydroxy compounds, e.g. alcohols

A61K 31/24 (2006.01)

A61K 31/616 (2006.01)

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

Event Publications

24 August 2006 PCT application entered the National Phase

  PCT publication WO2005/070868 Priority application(s): WO2005/070868

19 August 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005206228-Nitric oxide releasing prodrugs of diaryl2-(5H)-furanones as cyclooxygenase-2 inhibitors

2005206226-N-type calcium channel blockers